Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market

Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size Insights Forecasts to 2035

• The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size Was valued at USD 15.17 Billion in 2024
• The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size is Expected to Grow at a CAGR of around 15.82% from 2025 to 2035
• The Worldwide Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size is Expected to Reach USD 76.32 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size Was Worth Around USD 15.17 Billion In 2024 And Is Predicted To Grow To Around USD 76.32 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 15.82% From 2025 To 2035.  The global market for non-alcoholic fatty liver disease (NAFLD) provides multiple opportunities through new antifibrotic medications and metabolic therapies and through the development of noninvasive diagnostic methods and AI imaging systems and through combination treatment approaches and through growing public awareness of obesity and through increasing clinical research activities and through rising health expenditures in developing nations.

 

Market Overview

The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size refers to the worldwide healthcare industry, which establishes its operations through NAFLD diagnostic procedures and treatment solutions, NAFLD monitoring systems, and essential medical care functions. Additionally, the market for non-alcoholic fatty liver disease (NAFLD) treatments shows significant expansion because people become more aware of liver health and because obesity and metabolic disorders continue to rise. The healthcare industry faces increasing need for effective diagnostic tools and treatment solutions because both healthcare professionals and patients become more knowledgeable about NAFLD. Medical research progress has created new treatment methods which enable doctors to treat the disease and potentially cure it. The use of technology in healthcare through telemedicine and digital health solutions improves patient access to medical services while enabling earlier diagnosis which leads to better treatment results for NAFLD patients. The non-alcoholic fatty liver disease (NAFLD) market experiences growth because people want to improve their health through better lifestyle choices. Health professionals are increasingly advocating for dietary modifications and exercise regimens as essential components of managing NAFLD. The holistic approach allows patients to manage their health because it gives them complete control.

 

Report Coverage

This research report categorizes the non-alcoholic fatty liver disease (NAFLD) market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the non-alcoholic fatty liver disease (NAFLD) market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the non-alcoholic fatty liver disease (NAFLD) market. 

 

Driving Factors

Technological advancements in diagnostic methods for non-alcoholic fatty liver disease (NAFLD) market. The improved imaging methods of elastography and MRI provide better non-destructive measurement of liver fat content. The medical advancements lead to better results for patients while enabling doctors to discover NAFLD at an earlier stage which is essential for their complete treatment. The diagnostic tools market will expand because healthcare organizations begin using these technologies for improving their patient management systems. The use of artificial intelligence in diagnostic processes will create customized treatment solutions that improve operational efficiency in the Non-Alcoholic Fatty Liver Disease NAFLD Market.

 

Restraining Factors  

The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size faces multiple restricting factors which include absence of approved treatments and expensive diagnostic procedures and insufficient disease recognition and restricted public knowledge of the condition and difficult clinical study processes and problems with reimbursement and limited availability of expert hepatology treatment facilities.

 

Market Segmentation

The non-alcoholic fatty liver disease (NAFLD) market share is classified into diagnosis method and treatment type.

 

• The ultrasound segment dominated the market in 2024, approximately 40% and is projected to grow at a substantial CAGR during the forecast period.

Based on the diagnosis method, the non-alcoholic fatty liver disease (NAFLD) market is divided into ultrasound, CT Scan, MRI, and liver biopsy. Among these, the ultrasound segment dominated the market in 2024, approximately 40% and is projected to grow at a substantial CAGR during the forecast period. The system operates as a primary imaging solution for NAFLD testing and ongoing patient assessment. The system achieves fast execution times while maintaining patient comfort throughout its use for extensive population health assessments which results in increased usage and permanent market expansion.

• The lifestyle changes segment accounted for the largest share in 2024, approximately 57% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment type, the non-alcoholic fatty liver disease (NAFLD) market is divided into lifestyle changes, medications, surgical procedures, nutritional supplements. Among these, the lifestyle changes segment accounted for the largest share in 2024, approximately 57% and is anticipated to grow at a significant CAGR during the forecast period. The clinical guidelines prescribe weight management together with dietary changes and physical exercise as the primary treatment methods for NAFLD. The methods provide affordable treatment options which require no medical procedures and they remain easily accessible to patients. Strong adoption together with segment expansion occurs because people now understand obesity better and healthcare organizations focus on prevention and doctors prioritize chronic disease treatment.

 

Regional Segment Analysis of the Non-Alcoholic Fatty Liver Disease (NAFLD) Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the non-alcoholic fatty liver disease (NAFLD) market over the predicted timeframe.

North America is anticipated to hold the largest share of the non-alcoholic fatty liver disease (NAFLD) market over the predicted timeframe. The region maintains its market leadership through three key factors which include its efficient reimbursement systems and its successful clinical trials and its effective public awareness initiatives. The healthcare infrastructure of the region exists because of its high obesity and diabetes rates and its advanced medical facilities and its research activities in pharmaceutical development and its early implementation of new diagnostic and treatment methods.

 

Asia-Pacific is expected to grow at a rapid CAGR in the non-alcoholic fatty liver disease (NAFLD) market during the forecast period. Regional clinical-trial participation already comprises roughly one-third of industry-sponsored NAFLD studies which provide faster access to experimental therapies. South Korea and China implement national screening programs which lead to higher diagnosis rates while Japan's super-aging population increase creates higher demands for geriatric healthcare. Government investments which supports healthcare infrastructure development together with domestic biotech development create ongoing market growth.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the non-alcoholic fatty liver disease (NAFLD) market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Gilead Sciences, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Intercept Pharmaceuticals, Inc.
• Allergan (AbbVie Inc.)
• Genfit SA
• Madrigal Pharmaceuticals, Inc.
• Bristol Myers Squibb (BMS)
• Novartis AG
• Takeda Pharmaceutical Co., Ltd.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In May 2025, GSK announced the acquisition of efimosfermin for up to USD 2 billion, adding a Phase III-ready therapy that targeted the progression of steatotic liver disease.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the non-alcoholic fatty liver disease (NAFLD) market based on the below-mentioned segments: 

 

Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Diagnosis Method

• Ultrasound
• CT Scan
• MRI
• Liver Biopsy

 

Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Treatment Type

• Lifestyle Changes
• Medications
• Surgical Procedures
• Nutritional Supplements

 

Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the global NAFLD market?

A: The global NAFLD market is projected to grow from USD 15.17 billion in 2024 to USD 76.32 billion by 2035, registering a CAGR of 15.82% during the forecast period.

 

2. Which diagnosis method leads the NAFLD market?

A: Ultrasound dominates with a 40% share in 2024 due to noninvasive nature, affordability, quick procedure time, patient comfort, and widespread use as a primary imaging tool for screening and monitoring.

 

3. Which treatment segment holds the largest share?

A: Lifestyle changes lead with a 57% share in 2024, driven by clinical guideline recommendations, cost-effectiveness, noninvasive approach, preventive healthcare focus, obesity awareness, and strong physician emphasis on long-term disease management.

 

4. Which region holds the largest NAFLD market share?

A: North America leads due to advanced healthcare infrastructure, high obesity and diabetes prevalence, strong pharmaceutical research, effective reimbursement systems, active clinical trials, and early adoption of innovative diagnostics and therapies.

 

5. Which region is the fastest-growing NAFLD market?

A: Asia-Pacific grows fastest due to strong clinical-trial participation, national screening programs, expanding healthcare infrastructure, rising geriatric population, increasing government investments, and rapid domestic biotechnology development.